Lipocine Inc. (NASDAQ:LPCN) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.
Other research analysts have also issued reports about the stock. Canaccord Genuity set a $11.00 price objective on shares of Lipocine and gave the stock a “buy” rating in a report on Monday. Roth Capital set a $38.00 price objective on shares of Lipocine and gave the stock a “buy” rating in a report on Tuesday, June 20th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Lipocine in a research report on Wednesday, April 26th.
Shares of Lipocine (LPCN) opened at 4.32 on Thursday. The firm’s 50 day moving average is $4.45 and its 200-day moving average is $3.99. Lipocine has a 12 month low of $3.03 and a 12 month high of $5.90. The firm’s market capitalization is $83.21 million.
Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. On average, analysts expect that Lipocine will post ($1.15) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the company. KCG Holdings Inc. increased its stake in Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 7,219 shares during the period. LMR Partners LLP purchased a new stake in shares of Lipocine during the second quarter valued at about $173,000. Parametric Portfolio Associates LLC increased its stake in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after buying an additional 12,518 shares during the period. Federated Investors Inc. PA increased its stake in shares of Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 7,429 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock valued at $362,000 after buying an additional 6,191 shares during the period. 38.88% of the stock is owned by hedge funds and other institutional investors.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.